Teladoc Health, Inc. (NYSE:TDOC) CEO Jason N. Gorevic sold 25,000 shares of the business’s stock in a transaction dated Tuesday, April 6th. The stock was sold at an average price of $182.19, for a total transaction of $4,554,750.00. Following the transaction, the chief executive officer now owns 507,970 shares in the company, valued at $92,547,054.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE:TDOC traded up $4.57 during trading on Thursday, reaching $182.57. The company had a trading volume of 135,092 shares, compared to its average volume of 3,675,372. The company has a fifty day moving average of $208.17 and a two-hundred day moving average of $216.65. The stock has a market capitalization of $27.88 billion, a P/E ratio of -124.48 and a beta of 0.30. Teladoc Health, Inc. has a 12 month low of $135.52 and a 12 month high of $308.00. The company has a current ratio of 6.52, a quick ratio of 6.47 and a debt-to-equity ratio of 0.43.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 24th. The health services provider reported ($3.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($2.82). Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%. As a group, equities research analysts predict that Teladoc Health, Inc. will post -1.12 earnings per share for the current year.
TDOC has been the topic of several analyst reports. Craig Hallum boosted their price target on shares of Teladoc Health from $200.00 to $212.00 and gave the stock a “hold” rating in a report on Thursday, December 17th. Oppenheimer boosted their price target on shares of Teladoc Health from $250.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, March 3rd. Stifel Nicolaus dropped their target price on shares of Teladoc Health from $270.00 to $234.00 in a research note on Thursday, February 25th. Evercore ISI initiated coverage on shares of Teladoc Health in a research note on Tuesday, December 22nd. They set an “in-line” rating and a $215.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Teladoc Health from $263.00 to $226.00 and set a “buy” rating on the stock in a research note on Tuesday, March 23rd. Fourteen equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $241.38.
About Teladoc Health
Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.
Further Reading: What is Blockchain?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.